Patents by Inventor Frances Brook

Frances Brook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8921104
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: December 30, 2014
    Assignee: ISIS Innovation Limited
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Publication number: 20130171627
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 4, 2013
    Inventors: Herman WALDMANN, Paul J. FAIRCHILD, Richard GARDNER, Frances BROOK
  • Patent number: 8232100
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: July 31, 2012
    Assignee: Isis Innovation Limited
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Publication number: 20110014696
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Application
    Filed: July 21, 2010
    Publication date: January 20, 2011
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Patent number: 7781213
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: August 24, 2010
    Assignee: Isis Innovation Limited
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Publication number: 20090155898
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Application
    Filed: December 2, 2008
    Publication date: June 18, 2009
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Patent number: 7473556
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: January 6, 2009
    Assignee: Isis Innovation Limited
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Publication number: 20070269885
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Application
    Filed: April 24, 2007
    Publication date: November 22, 2007
    Inventors: Herman Waldmann, Paul Fairchild, Richard Gardner, Frances Brook
  • Patent number: 7247480
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: July 24, 2007
    Assignee: ISIS Innovation Limited
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Publication number: 20020131962
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells may be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Application
    Filed: April 30, 2002
    Publication date: September 19, 2002
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Publication number: 20020019047
    Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.
    Type: Application
    Filed: May 4, 2001
    Publication date: February 14, 2002
    Inventors: Herman Waldmann, Paul J. Fairchild, Richard Gardner, Frances Brook
  • Patent number: 6172055
    Abstract: Apoptotic cell death in a fully differentiated, non-dividing cell such as a neuron is caused by an abortive attempt of the cell to re-enter or pass through the mitotic cycle. Therefore, agents which prevent such entry or passage are effective in preventing, or at least delaying, apoptotic cell death and are therefore useful in the treatment of neurodegenerative diseases in general, including stroke, Alzheimer's disease, Parkinson's disease and motor-neuron disease in particular.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: January 9, 2001
    Assignee: Eisai Co., Ltd.
    Inventors: Lee Laurence Rubin, Susan Frances Brooks
  • Patent number: 5840719
    Abstract: Apoptotic cell death in a fully differentiated, non-dividing cell such as a neuron is caused by an abortive attempt of the cell to re-enter or pass through the mitotic cycle. Therefore, agents which prevent such entry or passage are effective in preventing, or at least delaying, apoptotic cell death and are therefore useful in the treatment of neurodegenerative diseases in general, including stroke, Alzheimer's disease, Parkinson's disease and motor-neuron disease in particular.
    Type: Grant
    Filed: May 8, 1996
    Date of Patent: November 24, 1998
    Assignee: Eisai Company, Ltd.
    Inventors: Lee Laurence Rubin, Susan Frances Brooks, deceased